{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:11:23Z","timestamp":1789042283114,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Key Project of the University of South China","award":["Grant No. USC [2019] No. 02"],"award-info":[{"award-number":["Grant No. USC [2019] No. 02"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acquired cisplatin resistance limits platinum chemotherapy efficacy in non\u2013small cell lung cancer (NSCLC) and is accompanied by tumor immune microenvironment (TME) remodeling. We integrated public NSCLC single-cell RNA-seq datasets to compare cellular composition and CellChat-inferred communication between post-chemotherapy remission and relapse\/resistant tumors, and validated ZUP1 expression and prognostic relevance in TCGA and external cohorts. In cisplatin-resistant A549\/R and SK-MES-1\/R cells, we generated stable ZUP1 knockdown and assessed proliferation, tumorsphere growth and formation, apoptosis (Annexin V\/PI) and BAX\/BCL2 expression, and xenograft growth. Tumor cell\u2013peripheral Treg co-cultures were used to quantify the proportion of FOXP3\u207a cells within the gated CD4\u207a population. Natural-product screening was guided by molecular docking, and ZUP1\u2013compound binding was evaluated by surface plasmon resonance (SPR). Peimisine responses were compared between parental and cisplatin-resistant cells. In A549\/R cells, experimentally measured viability across a peimisine\u2013cisplatin concentration matrix and cisplatin dose\u2013response curves at fixed peimisine concentrations were used to evaluate changes in cisplatin sensitivity. Resistant tumors exhibited remodeled cellular composition and enhanced intercellular communication, including increased epithelial-to-Treg signaling. ZUP1 was upregulated in resistant models and associated with unfavorable prognosis. ZUP1 knockdown suppressed growth and tumorsphere formation, increased apoptosis, reduced tumorigenicity in vivo, and reduced the proportion of CD4\u207aFOXP3\u207a Treg-like cells in co-culture. Peimisine directly bound ZUP1 by SPR, inhibited resistant cell growth, and was associated with lower estimated cisplatin IC\u2085\u2080 values in A549\/R cells at fixed peimisine concentrations. ZUP1 contributes to the maintenance of cisplatin-resistant growth and is associated with enhanced Treg-related immunosuppressive signaling in NSCLC. Peimisine directly binds ZUP1 and may serve as a preliminary natural-product lead for further target-validation and combination studies.<\/jats:p>","DOI":"10.1038\/s41598-026-70626-y","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:05:24Z","timestamp":1788995124000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ZUP1 contributes to cisplatin resistance and treg-related signaling in non\u2013small cell lung cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Wanyan","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixuan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhike","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"70626_CR1","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst, R. S., Morgensztern, D. & Boshoff, C. The biology and management of non-small cell lung cancer. Nature 553, 446\u2013454. https:\/\/doi.org\/10.1038\/nature25183 (2018).","journal-title":"Nature"},{"key":"70626_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ctrv.2016.01.003","volume":"44","author":"DA Fennell","year":"2016","unstructured":"Fennell, D. A. et al. Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat. Rev. 44, 42\u201350. https:\/\/doi.org\/10.1016\/j.ctrv.2016.01.003 (2016).","journal-title":"Cancer Treat. Rev."},{"key":"70626_CR3","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1200\/jco.23.01476","volume":"41","author":"HA Yu","year":"2023","unstructured":"Yu, H. A. et al. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. J. Clin. oncology: official J. Am. Soc. Clin. Oncol. 41, 5363\u20135375. https:\/\/doi.org\/10.1200\/jco.23.01476 (2023).","journal-title":"J. Clin. oncology: official J. Am. Soc. Clin. Oncol."},{"key":"70626_CR4","doi-asserted-by":"publisher","unstructured":"Liu, Y., Liang, J., Zhang, Y. & Guo, Q. Drug resistance and tumor immune microenvironment: An overview of current understandings (Review). Int. J. Oncol. 65 https:\/\/doi.org\/10.3892\/ijo.2024.5684 (2024).","DOI":"10.3892\/ijo.2024.5684"},{"key":"70626_CR5","doi-asserted-by":"publisher","unstructured":"Chen, S. H. & Chang, J. Y. New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment. Int. J. Mol. Sci. 20 https:\/\/doi.org\/10.3390\/ijms20174136 (2019).","DOI":"10.3390\/ijms20174136"},{"key":"70626_CR6","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41467-021-21043-4","volume":"12","author":"Y Liu","year":"2021","unstructured":"Liu, Y. et al. Tumour heterogeneity and intercellular networks of nasopharyngeal carcinoma at single cell resolution. Nat. Commun. 12, 741. https:\/\/doi.org\/10.1038\/s41467-021-21043-4 (2021).","journal-title":"Nat. Commun."},{"key":"70626_CR7","doi-asserted-by":"publisher","first-page":"4734","DOI":"10.1016\/j.cell.2021.08.003","volume":"184","author":"K Pelka","year":"2021","unstructured":"Pelka, K. et al. Spatially organized multicellular immune hubs in human colorectal cancer. Cell 184, 4734\u20134752e4720. https:\/\/doi.org\/10.1016\/j.cell.2021.08.003 (2021).","journal-title":"Cell"},{"key":"70626_CR8","doi-asserted-by":"publisher","first-page":"217116","DOI":"10.1016\/j.canlet.2024.217116","volume":"598","author":"C Yang","year":"2024","unstructured":"Yang, C., Deng, X., Tang, Y., Tang, H. & Xia, C. Natural products reverse cisplatin resistance in the hypoxic tumor microenvironment. Cancer Lett. 598, 217116. https:\/\/doi.org\/10.1016\/j.canlet.2024.217116 (2024).","journal-title":"Cancer Lett."},{"key":"70626_CR9","doi-asserted-by":"publisher","unstructured":"Jia, H. et al. Post-translational modifications of cancer immune checkpoints: mechanisms and therapeutic strategies. Mol. Cancer. 24 https:\/\/doi.org\/10.1186\/s12943-025-02397-5 (2025).","DOI":"10.1186\/s12943-025-02397-5"},{"key":"70626_CR10","doi-asserted-by":"publisher","first-page":"e1204","DOI":"10.1002\/ctm2.1204","volume":"13","author":"C Sampson","year":"2023","unstructured":"Sampson, C. et al. The roles of E3 ubiquitin ligases in cancer progression and targeted therapy. Clin. translational Med. 13, e1204. https:\/\/doi.org\/10.1002\/ctm2.1204 (2023).","journal-title":"Clin. translational Med."},{"key":"70626_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.5483\/BMBRep.2023-0037","volume":"56","author":"EH Jo","year":"2023","unstructured":"Jo, E. H., Kim, M. Y., Lee, H. J. & Park, H. S. Ubiquitin E3 ligases in cancer: somatic mutation and amplification. BMB Rep. 56, 265\u2013274. https:\/\/doi.org\/10.5483\/BMBRep.2023-0037 (2023).","journal-title":"BMB Rep."},{"key":"70626_CR12","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41568-023-00633-y","volume":"23","author":"G Dewson","year":"2023","unstructured":"Dewson, G., Eichhorn, P. J. A. & Komander, D. Deubiquitinases in cancer. Nat. Rev. Cancer. 23, 842\u2013862. https:\/\/doi.org\/10.1038\/s41568-023-00633-y (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"70626_CR13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s12964-024-01633-7","volume":"22","author":"SK Hsu","year":"2024","unstructured":"Hsu, S. K. et al. Deubiquitinating enzymes: potential regulators of the tumor microenvironment and implications for immune evasion. Cell. communication signaling: CCS. 22, 259. https:\/\/doi.org\/10.1186\/s12964-024-01633-7 (2024).","journal-title":"Cell. communication signaling: CCS"},{"key":"70626_CR14","doi-asserted-by":"publisher","first-page":"e2303807","DOI":"10.1002\/advs.202303807","volume":"10","author":"J Ren","year":"2023","unstructured":"Ren, J. et al. Deubiquitylating Enzymes in Cancer and Immunity. Adv. Sci. (Weinheim Baden-Wurttemberg Germany). 10, e2303807. https:\/\/doi.org\/10.1002\/advs.202303807 (2023).","journal-title":"Adv. Sci. (Weinheim Baden-Wurttemberg Germany)"},{"key":"70626_CR15","doi-asserted-by":"publisher","first-page":"1051998","DOI":"10.3389\/fimmu.2022.1051998","volume":"13","author":"W Zhang","year":"2022","unstructured":"Zhang, W., Li, S., Li, C., Li, T. & Huang, Y. Remodeling tumor microenvironment with natural products to overcome drug resistance. Front. Immunol. 13, 1051998. https:\/\/doi.org\/10.3389\/fimmu.2022.1051998 (2022).","journal-title":"Front. Immunol."},{"key":"70626_CR16","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.2174\/0109298673274796240116105555","volume":"31","author":"Y Vijayan","year":"2024","unstructured":"Vijayan, Y., Sandhu, J. S. & Harikumar, K. B. Modulatory Role of Phytochemicals\/Natural Products in Cancer Immunotherapy. Curr. Med. Chem. 31, 5165\u20135177. https:\/\/doi.org\/10.2174\/0109298673274796240116105555 (2024).","journal-title":"Curr. Med. Chem."},{"key":"70626_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13073-023-01164-9","volume":"15","author":"J Hu","year":"2023","unstructured":"Hu, J. et al. Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing. Genome Med. 15, 14. https:\/\/doi.org\/10.1186\/s13073-023-01164-9 (2023).","journal-title":"Genome Med."},{"key":"70626_CR18","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1016\/j.cell.2025.03.018","volume":"188","author":"Z Liu","year":"2025","unstructured":"Liu, Z. et al. A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer. Cell 188, 3081\u20133096e3019. https:\/\/doi.org\/10.1016\/j.cell.2025.03.018 (2025).","journal-title":"Cell"},{"key":"70626_CR19","doi-asserted-by":"publisher","first-page":"111856","DOI":"10.1016\/j.mrfmmm.2024.111856","volume":"828","author":"H Umar","year":"2024","unstructured":"Umar, H. et al. Platinum-based targeted chemotherapies and reversal of cisplatin resistance in non-small cell lung cancer (NSCLC). Mutat. Res. 828, 111856. https:\/\/doi.org\/10.1016\/j.mrfmmm.2024.111856 (2024).","journal-title":"Mutat. Res."},{"key":"70626_CR20","doi-asserted-by":"publisher","unstructured":"Yeldag, G., Rice, A. & Del R\u00edo Hern\u00e1ndez, A. Chemoresistance and the Self-Maintaining Tumor Microenvironment. Cancers 10 https:\/\/doi.org\/10.3390\/cancers10120471 (2018).","DOI":"10.3390\/cancers10120471"},{"key":"70626_CR21","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s00262-015-1725-1","volume":"64","author":"JD Phillips","year":"2015","unstructured":"Phillips, J. D. et al. Preferential expansion of pro-inflammatory Tregs in human non-small cell lung cancer. Cancer Immunol. immunotherapy: CII. 64, 1185\u20131191. https:\/\/doi.org\/10.1007\/s00262-015-1725-1 (2015).","journal-title":"Cancer Immunol. immunotherapy: CII"},{"key":"70626_CR22","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/s42003-022-04356-y","volume":"5","author":"P Devi-Marulkar","year":"2022","unstructured":"Devi-Marulkar, P. et al. Regulatory T cells infiltrate the tumor-induced tertiary lympho\u00efd structures and are associated with poor clinical outcome in NSCLC. Commun. biology. 5, 1416. https:\/\/doi.org\/10.1038\/s42003-022-04356-y (2022).","journal-title":"Commun. biology"},{"key":"70626_CR23","doi-asserted-by":"publisher","first-page":"6705","DOI":"10.1158\/0008-5472.Can-14-1482","volume":"74","author":"EK Kim","year":"2014","unstructured":"Kim, E. K. et al. Tumor-derived osteopontin suppresses antitumor immunity by promoting extramedullary myelopoiesis. Cancer Res. 74, 6705\u20136716. https:\/\/doi.org\/10.1158\/0008-5472.Can-14-1482 (2014).","journal-title":"Cancer Res."},{"key":"70626_CR24","doi-asserted-by":"publisher","unstructured":"Vakrakou, A. G. et al. Osteopontin Regulates Treg Cell Stability and Function with Implications for Anti-Tumor Immunity and Autoimmunity. Cancers 16 https:\/\/doi.org\/10.3390\/cancers16172952 (2024).","DOI":"10.3390\/cancers16172952"},{"key":"70626_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.molcel.2018.02.023","volume":"70","author":"D Kwasna","year":"2018","unstructured":"Kwasna, D. et al. Discovery and Characterization of ZUFSP\/ZUP1, a Distinct Deubiquitinase Class Important for Genome Stability. Mol. Cell. 70, 150\u2013164e156. https:\/\/doi.org\/10.1016\/j.molcel.2018.02.023 (2018).","journal-title":"Mol. Cell"},{"key":"70626_CR26","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.molcel.2018.02.024","volume":"70","author":"P Haahr","year":"2018","unstructured":"Haahr, P. et al. ZUFSP Deubiquitylates K63-Linked Polyubiquitin Chains to Promote Genome Stability. Mol. Cell. 70, 165\u2013174e166. https:\/\/doi.org\/10.1016\/j.molcel.2018.02.024 (2018).","journal-title":"Mol. Cell"},{"key":"70626_CR27","doi-asserted-by":"publisher","first-page":"e70419","DOI":"10.1096\/fj.202401661RRR","volume":"39","author":"W Hao","year":"2025","unstructured":"Hao, W. et al. ZUP1 is a key component of the MAVS complex and acts as a protector of host against viral invasion. FASEB journal: official publication Federation Am. Soc. Experimental Biology. 39, e70419. https:\/\/doi.org\/10.1096\/fj.202401661RRR (2025).","journal-title":"FASEB journal: official publication Federation Am. Soc. Experimental Biology"},{"key":"70626_CR28","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.ccell.2016.10.010","volume":"30","author":"SO Lim","year":"2016","unstructured":"Lim, S. O. et al. Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer cell. 30, 925\u2013939. https:\/\/doi.org\/10.1016\/j.ccell.2016.10.010 (2016).","journal-title":"Cancer cell."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-70626-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-70626-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-70626-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:30:11Z","timestamp":1789039811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-70626-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["70626"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-70626-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Human peripheral blood mononuclear cell collection was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of The Affiliated Nanhua Hospital, University of South China (Approval No. 202402111). Written informed consent was obtained from all healthy donors before sample collection. All animal experiments were approved by the Animal Ethics Committee of the University of South China (Approval No. 20249515) and were performed in accordance with relevant institutional guidelines and regulations.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all healthy donors prior to PBMC collection. Donor information was anonymized prior to analysis.","order":3,"name":"Ethics","label":"Patient consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"28346"}}